Neogen Corporation (NEOG) Stock Price & How to Invest

Neogen Corporation, based in Lansing, Michigan and incorporated in 1981, develops and markets diagnostic products and test kits that detect contamination in the food chain and support animal health. It operates in two segments: Food Safety (roughly 70% of sales after the 3M Food Safety acquisition), which tests for pathogens, spoilage organisms, toxins, and allergens, and Animal Safety, which sells veterinary instruments, diagnostics, disinfectants, rodent and insect control products, and life science reagents. The Food Safety segment is now the larger contributor and the strategic core following the transformative 3M deal.

The investment picture is dominated by that 3M integration. Neogen took on significant leverage and has posted GAAP net losses in recent quarters, largely from acquisition-related amortization, even as adjusted EBITDA stays positive. Management is streamlining the portfolio, agreeing in 2026 to sell its global genomics business (GeneSeek) to Zoetis for ~$160 million with proceeds earmarked for debt reduction. The bull case rests on stable, recurring testing demand and deleveraging; the bear case centers on execution risk, share loss to larger rivals, and the time needed to reach durable profitability.

Integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization. The company carries elevated leverage and competes against larger, better-capitalized players in both food and animal diagnostics. Core revenue in the Animal Safety segment declined in recent quarters, showing uneven demand. The genomics divestiture removes a ~$90 million revenue line, so the remaining business must carry growth on its own. The stock has been volatile and traded near multi-year lows, so sentiment can swing sharply on quarterly execution.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Neogen Corporation's investor relations page or your broker.

• Revenue (FY2026 guidance): ~$857-860M
• Adjusted EBITDA (FY2026): ~$175M
• Q3 FY2026 revenue: ~$211M
• Q3 FY2026 net loss: ~-$17M
• Market cap: ~$2.1B
• Share price: ~$9-10

Neogen posts positive adjusted EBITDA (~$175M target) but recent GAAP results show net losses, largely from 3M acquisition amortization. The gap between adjusted and reported figures, plus elevated debt, is why valuation is contested despite a multi-billion-dollar market cap on roughly $855M of sales.

There are three common ways to get NEOG exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so NEOG sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where NEOG fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

NEOG is a turnaround-and-integration story where the investment case hinges on whether Neogen can convert its expanded scale into profitable, cash-generating growth while paying down debt.

Whether NEOG is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NEOG a buy?, and where the stock could go from here in the NEOG stock forecast.

For income investors, whether NEOG pays a dividend and how the payout looks is covered in does NEOG pay a dividend?